Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis

Rheumatology (United Kingdom)

Volumn 54, Issue 8, 2015, Pages 1345-1350

  Faurschou, Mikkel ^a   Mellemkjaer, Lene ^b   Voss, Anne ^c   Keller, Kresten Krarup ^d   Hansen, Ib Tonder ^d   Baslund, Bo ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bladder cancer; Granulomatosis with polyangiitis; Leukaemia; Long term follow up; Malignancy; Non melanoma skin cancer

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOID LEUKEMIA; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; SURVIVAL TIME; WEGENER GRANULOMATOSIS;

EID: 84939540479     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu372     Document Type: Article

References (20)

1. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
2. Pedersen-Bjergaard J, Ersboll J, Hansen VL et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988;318:1028-32.
3. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52.
4. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5.
5. Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5.
6. Holle JU, Gross WL, Latza U et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63:257-66.
7. Heijl C, Harper L, Flossmann O et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011;70:1415-21.
8. Silva F, Seo P, Schroeder DR et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 2011;63: 2495-503.
9. Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011;63: 1435-45.
10. Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
11. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63:1307-11.
12. Flossmann O, Berden A, De GK et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.
13. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8.
14. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101-7.
15. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997;44:535-9.
16. Ingvar A, Smedby KE, Lindelof B et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 2010; 25:2764-71.
17. Setshedi M, Epstein D, Winter TA et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012;27: 385-9.
18. Sorensen HT, Mellemkjaer L, Nielsen GL et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709-11.
19. Pedersen-Bjergaard J, Specht L, Larsen SO et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987;2:83-8.
20. de Groot K, Harper L, Jayne DR et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.